Recruiting

Tyrosine Kinase Inhibitors

Sponsor:

UCLA

Code:

NCT06229860

Conditions

Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Interview

Study Details

Brief summary:

This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Conditions

Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia

Study ID

NCT06229860

Start date

Jan 25, 2024

Status verified date

Mar, 2026

Completion date

Dec, 2026

Anticipated

Primary completion date

Mar 19, 2025

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 18 years of age or older
  • Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
  • Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
  • A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
  • A member of a patient support group organized by the CML Buster Foundation
  • Do not meet any of the criteria listed under "Exclusion Requirements"

Exclusion Criteria:

  • Unable to read and speak English
  • Impaired decisional capacity to consent

Study Design

Enrollment

75 participants

Anticipated

Interventions and Outcome Measures

Arms

Adult patients with CML in chronic phase (CML-CP)

Interventions

Interview

In-person interview with the study coordinator to complete study questionnaire.

Primary outcome measure

  • Assessment of adherence to TKI medication [ Time Frame: Up to 1 year ]
  • Personality assessment [ Time Frame: Up to 1 year ]
  • Assessment of quality of Life [ Time Frame: Up to 1 year ]
  • Assessment of quality of Life and symptom burden [ Time Frame: Up to 1 year ]

Central Contacts and Locations

Central contacts

Chao Family Comprehensive Cancer Center University of California, Irvine

1-877-827-8839ucstudy@uci.edu

Locations

Chao Family Comprehensive Cancer Center University of California, Irvine

Recruiting

Orange, California, United States, 92868

Contacts

Mahtab Jafari, Pharm.D

877-827-8839ucstudy@uci.edu

More Information

Sponsor

University of California, Irvine

Last update posted

Mar 10, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, Irvine on 2026-03-10.